![](https://endpts.com/wp-content/uploads/2023/01/Detlev-Biniszkiewicz.jpg)
Detlev Biniszkiewicz, NextPoint Therapeutics CEO
Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise
An MPM Capital-backed biotech based on the discovery of a new immune checkpoint inhibitor has secured about $80 million in financing, with former executives from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.